blue cross blue shield - tennessee H. pylori Coverage

Coverage Criteria for H. pylori Testing

inv-01: UBT/SAT - Adult diagnostic

Covered when ANY of the following adult indications are met:

Adult diagnostic indications for UBT/SAT: dyspeptic symptoms; active peptic ulcer disease (PUD); past PUD without documented prior H. pylori cure; low-grade gastric MALT lymphoma; history of endoscopic resection of early gastric cancer (EGC); gastric intestinal metaplasia (GIM); uninvestigated dyspepsia in patients <60 years without alarm features; initiating chronic NSAID therapy; unexplained iron deficiency anemia; chronic immune thrombocytopenic purpura (ITP); family history of gastric cancer; first-generation immigrant from high-prevalence area.

Source: Policy indications listed in III. Indications and/or Limitations of Coverage (adult).

inv-02: Test-of-eradication

Covered for post-treatment confirmation when ALL of the following are met:

Post-treatment eradication testing: Testing is performed at least 4 weeks after completion of therapy; applies to any patient with an H. pylori–associated ulcer, patients with persistent dyspepsia after appropriate antibiotic treatment for H. pylori, patients with gastric MALT lymphoma, and individuals who have undergone resection of early gastric cancer.>=4 weeks post-treatment

Policy specifies timing and applicable follow-up scenarios.

inv-03: Pediatric indications

Covered pediatric indications:

Pediatric UBT/SAT diagnostic and re-evaluation: UBT or stool antigen testing meets coverage for pediatric patients for evaluation of chronic immune thrombocytopenic purpura (ITP) and for re-evaluation to confirm eradication at least 4 weeks post-treatment.>=4 weeks post-treatment for eradication

From pediatric-specific coverage statements.

Pediatric biopsy-based testing: Biopsy-based endoscopic histology plus rapid urease test (RUT) or culture with susceptibility testing meets coverage for children with gastric or duodenal ulcers and for children with refractory iron deficiency anemia after other causes have been ruled out.

Policy lists pediatric biopsy indications and ESPGHAN/NASPGHAN recommendations to biopsy when treatment will be offered.

inv-04: Adult biopsy-based testing

Covered when ALL of the following are met:

Adult biopsy-based testing: Biopsy histology plus rapid urease test (RUT) or culture with susceptibility testing meets coverage for adult patients undergoing endoscopy or for those with alarm symptoms for diagnosis of H. pylori infection.

Policy describes biopsy indications for adults and recommends histology/culture when endoscopy is performed.

inv-05: Indications for testing

Covered when ANY of the following indication-based criteria are met per referenced guidelines:

Indication-based testing: Active peptic ulcer disease; past history of peptic ulcer disease (unless prior documented cure of H. pylori); low-grade gastric MALT lymphoma; history of endoscopic resection of early gastric cancer; uninvestigated dyspepsia (age thresholds vary by guideline); unexplained iron deficiency anemia after appropriate evaluation; idiopathic/immune thrombocytopenic purpura (ITP); first-degree relatives or family history of gastric cancer; first-generation immigrants from high-prevalence areas or patients from high-prevalence regions; select high-risk racial/ethnic groups (eg, Latino, African American); patients initiating chronic NSAID or antiplatelet therapy per some recommendations.

Sources: ACG/CAG, AGA, Houston Consensus, Maastricht.

inv-06: Diagnostic methods and timing

Testing method and timing criteria:

Preferred tests: Use 13C-urea breath test (UBT) or stool antigen (HpSAg) test for initial diagnosis and for confirmation of eradication; use biopsy-based rapid urease test (RUT) and histology when endoscopy is performed.

NICE, Maastricht, AGA recommend UBT or stool antigen as preferred noninvasive tests; biopsy/RUT when endoscopy indicated.

Pre-test medication discontinuation: Discontinue proton pump inhibitors (PPIs) at least 2 weeks before testing; discontinue antibiotics and bismuth at least 4 weeks before testing to avoid false-negative results.PPI 2 weeks; antibiotics/bismuth 4 weeks

NICE and Maastricht guidance on required washout periods.

inv-07: Eradication confirmation

Post-treatment confirmation:

Eradication testing: UBT is preferred for confirmation of eradication; validated monoclonal stool antigen tests are an alternative; testing should be performed at least 4 weeks after completion of therapy (some guidance allows 6–8 weeks for peptic ulcer follow-up).>=4 weeks post-therapy

Maastricht, Kato et al., and policy statements specify timing and preferred tests for eradication confirmation.

inv-08: Clarithromycin resistance and susceptibility testing

When considering clarithromycin-based therapy:

Clarithromycin guidance: Reserve clarithromycin-based triple therapy for first-line use only when local clarithromycin resistance is documented to be <15% and the patient has no prior macrolide exposure; obtain clarithromycin susceptibility information (molecular or culture-based) when clarithromycin-based therapy is being considered to guide treatment choice.<15% resistance

ACG recommendation and Maastricht guidance; PCR-based genotypic resistance assays can inform clarithromycin susceptibility.

inv-09: Pediatric indications and methods

Pediatric testing recommendations:

Children and adolescents: Do not use a 'test-and-treat' strategy for asymptomatic children; perform testing in children with gastric or duodenal peptic ulcer disease; when treatment will be offered, obtain biopsies for RUT/culture and histology; noninvasive tests (UBT, stool antigen) are preferred for diagnosis when endoscopy is not performed; avoid single serology tests for diagnosis in children.

ESPGHAN/NASPGHAN and pan‑European pediatric guidance recommend biopsy when treatment is planned and discourage serology and test-and-treat strategies in asymptomatic children.

inv-10: Covered when ALL of the following are met

Coverage aligns with expert consensus recommendations where testing/treatment is indicated.

Indications for testing: Test for H. pylori infection in patients with current or past gastric or duodenal ulcers; patients with uninvestigated dyspepsia; patients with gastric MALT lymphoma; individuals with family history of gastric cancer; first-generation immigrants from high-prevalence areas; consider testing certain high-risk racial/ethnic groups.

Houston Consensus statements 1–7.

Initial diagnostic tests: Use tests that detect active infection—UBT, stool antigen (HpSAg), or histology when endoscopy is indicated—for initial diagnosis; do not use serology for detection of active infection.

Houston Consensus Statement 20 and Statement 22; policy excludes serology for active infection.

Pre-test medication management: Stop bismuth and antibiotics at least 4 weeks prior to testing for active infection.>=4 weeks

UBT (urea breath test) or stool antigen testing does not meet coverage for asymptomatic pediatric (<18 years) and asymptomatic adult (>18 years) patients. Testing is also not covered for adults with typical gastroesophageal reflux disease (GERD) symptoms who do not have a history of peptic ulcer disease (PUD).

Serologic (antibody) testing does not meet coverage for the diagnosis of H. pylori infection because serology cannot reliably distinguish active infection from past exposure or cured infection, and serologic tests have limited positive predictive value in low- or average-prevalence populations.

Biopsy-based histology with Rapid Urease Test (RUT) or culture plus susceptibility testing does not meet coverage in pediatric patients for evaluation of functional abdominal pain, as part of initial investigation of iron deficiency anemia, or when investigating short stature. Pediatric guidelines recommend biopsy-based testing only when treatment is likely to be offered or when children have gastric or duodenal peptic ulcer disease.

Testing with UBT, stool antigen, or biopsy-based methods does not meet coverage if performed within the washout periods after interfering medications: stop antibiotics and bismuth ≥4 weeks before testing and stop proton pump inhibitors (PPIs) ≥2 weeks before testing, since recent use may produce false-negative results.

Concurrent, simultaneous use of multiple H. pylori test modalities (e.g., performing UBT and stool antigen testing and/or biopsy-based testing at the same time) does not meet coverage, because combined simultaneous testing does not improve clinical understanding.

Nucleic acid testing for H. pylori (including PCR, 16S/23S rRNA assays, and next-generation sequencing) does not meet coverage for routine diagnosis due to limited practicality and high cost, despite high analytic accuracy in select studies.

Office-based rapid serology kits and routine point-of-care serological testing are not recommended by guideline bodies (e.g., NICE, ASCP) and are therefore excluded as preferred diagnostic methods for detecting active H. pylori infection.

Serology should not be utilized for detection of active H. pylori infection; expert consensus explicitly recommends using tests that detect active infection (UBT, stool antigen, or histology when endoscopy is indicated) instead of serologic assays.

Serologic testing for H. pylori is considered not medically necessary for diagnosis of active infection because it cannot discriminate active from past infection and is discouraged by clinical guidance.

Routine testing and treatment of asymptomatic individuals (including children) without guideline-based indications is not recommended and does not meet coverage. Testing should be reserved for indications supported by guidelines (for example, active or past PUD, certain anemia or ITP cases, or other guideline-specified scenarios).

Once eradication has been documented using appropriate tests for active infection, further routine H. pylori testing is not recommended. Post-eradication repeat testing without clinical indication does not meet coverage.

Provider Actions, Documentation, and Operational Notes

Documentation Required

Indication documentation and results

Urea breath test (UBT) or stool antigen (HpSAg) testing is covered for diagnosis and for post-treatment confirmation of active H. pylori infection when documentation supports an indicated clinical reason. Document the patient indication (for example: dyspepsia, active or past peptic ulcer disease, low-grade gastric MALT lymphoma, prior endoscopic resection of early gastric cancer, gastric intestinal metaplasia, unexplained iron deficiency anemia, idiopathic thrombocytopenic purpura, first-generation immigrant from high-prevalence area, family history of gastric cancer, initiation of chronic NSAID therapy, or uninvestigated dyspepsia in patients <60 without alarm features) and the test result.

Indication and result must be present in the medical record.
For test-of-eradication, documentation must show testing at least 4 weeks after completion of antibiotics and appropriate cessation of interfering medications (see below).

Denial Risk

Avoid serology for active infection

Serologic (antibody) testing does not distinguish active from past infection and is not acceptable for diagnosis of active H. pylori infection or for test-of-eradication confirmation. Use only tests that detect active infection (UBT, stool antigen, or histology when endoscopy is clinically indicated).

Coding and FDA Device Notes

FDA-cleared UBT devices and LDT notemixed

BreathTek UBT	BreathTek UBT for H. pylori Kit (FDA-cleared device for initial diagnosis and post-treatment monitoring)
BreathTek UBiT	BreathTek UBiT for H. pylori (Meretek) — UBT devices cleared for adults
PyloPlus UBT System	PyloPlus UBT System (ARJ Medical Inc.) — UBT for adults

Background and Rationale

Helicobacter pylori is a spiral-shaped, gram-negative bacterium that colonizes the stomach, causes chronic gastritis, and is associated with peptic ulcer disease, gastric adenocarcinoma, and mucosa-associated lymphoid tissue (MALT) lymphoma. Testing aims to identify active infection to guide eradication therapy and to confirm eradication after treatment using tests that detect active infection (UBT, stool antigen, or histology when endoscopy is indicated).

Definitions and Abbreviations

Helicobacter pylori (HP) — key facts

DefinitionHelicobacter pylori is a spiral-shaped, gram-negative bacterium that colonizes the stomach lining and is associated with chronic gastritis, peptic ulcer disease, gastric adenocarcinoma, and gastric MALT lymphoma.

PathophysiologyColonizes acidic gastric environment and causes chronic stomach inflammation.

Clinical relevanceTesting is performed to detect active infection for treatment and to confirm eradication post-treatment.

Associated conditionsPeptic ulcer disease, chronic gastritis, gastric adenocarcinoma, MALT lymphoma.

Common abbreviations

UBTUrea Breath Test (UBT)

OpenPayer

Helicobacter pylori testing — Coverage and limitations for diagnostic testing

Coverage Criteria for H. pylori Testing

Provider Actions, Documentation, and Operational Notes

Coding and FDA Device Notes

Background and Rationale

Definitions and Abbreviations